Supplementary Material

Supplementary Figures



Figure S1. Identification of SC75741 as a TDP25 degradator

A. High-throughput screening image, MG132 is shown as a negative control, Ibudilast is shown as a positive control, SC75741 is shown as a candidate agent.

Scale bar, 1000 µm;

- B. H4GT25 cells were pretreated with 1 μ g/mL DOX for 24h, treated with DMSO, ibudilast (10 μ M) or SC75741 (5 μ M) for another 24h, live cell imaging was performed with confocal microscopy. Scale bar, 20 μ m
- C. H4GT25 cells were pretreated with 1 μ g/mL DOX for 24h, treated with DMSO, ibudilast (10 μ M) or SC75741 (5 μ M) for another 24h, live cell imaging was performed with confocal microscopy. Quantification of the aggregates per cell (data represents mean ± SD; DMSO (n = 190 cells), Ibudilast (n = 336 cells), SC75741 (n = 233 cells), ****p < 0.0001, ***p < 0.001, two-tailed t test).
- D. H4GT25 cells were pretreated with 1 μ g/mL DOX for 24h, treated with SC75741(0 μ M, 0.1 μ M, 0.5 μ M, 1 μ M, 5 μ M and 10 μ M) for another 24h. Cell lysates were immunoblotted with indicated antibodies. The numbers under the blot represent the gray scale quantification (GFP/Tubulin).
- E. SH-SY5Y-GT25 cells were pretreated with 1 μ g/mL DOX for 24h, treated with SC75741(0 μ M, 0.1 μ M, 0.5 μ M, 1 μ M, 5 μ M and 10 μ M) for another 24h. Cell lysates were immunoblotted with indicated antibodies. The numbers under the blot represent the gray scale quantification (GFP/Tubulin).
- F. H4GT25 cells were pretreated with 1 μ g/mL DOX for 24h, treated with 1 μ M MG132 for 12h, along with DMSO, ibudilast (10 μ M) or SC75741 (5 μ M) for 24h. Cell lysates were immunoblotted with indicated antibodies. The numbers under the blot represent the gray scale quantification (GFP/Tubulin).
- G. H4GT25 cells were pretreated with 1 μ g/mL DOX for 24h, treated with 0.5 mM arsenite for 1h, along with DMSO, ibudilast (10 μ M) or SC75741 (5 μ M) for 24h. Cell lysates were immunoblotted with indicated antibodies. The numbers under the blot represent the gray scale quantification (GFP/Tubulin).
- H. H4GT25 cells were pretreated with 1 μ g/mL DOX for 24h, treated with or without 5 μ M SC75741 for another 24h, total lysates, RIPA lysates and urea lysates were immunoblotted with indicated antibodies. The numbers under the blot represent the gray scale quantification (GFP/Tubulin).



Figure S2. SC75741 increases clearance of ALS-related pathogenic mutations-

induced aggregation in animal cells

- A. N2A cells were transfected with indicated plasmids for 24h, treated with or without 5 μ M SC75741 for another 24h. Cell lysates were immunoblotted with indicated antibodies. The numbers under the blot represent the gray scale quantification (GFP/Tubulin).
- B. N2A cells were transfected with indicated plasmids for 24h, treated with or without 5 μ M SC75741 for another 24h, the GFP fluorescence was analyzed by fluorescence microscopy. (data represent mean \pm SD; n = 6, ****p < 0.0001, two-tailed *t* test).



Figure S3



- A. SH-SY5YKT25 cells were pretreated with 1 μ g/mL DOX for 24h, treated with DMSO, ibudilast (10 μ M) or SC75741 (5 μ M) for another 24h, and the Keima-TDP25 fluorescence was analyzed by fluorescence microscopy.
- B. SH-SY5YKT25 cells were pretreated with 1 μ g/mL DOX for 24h, treated with DMSO, ibudilast (10 μ M) or SC75741 (5 μ M) for another 24h, and the Keima-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with

cells treated with DMSO. (data represent mean \pm SD.; n = 7, ****p < 0.0001, ***p < 0.001, two-tailed *t* test).

- C. HEK293 WT and ATG5-/- cells were transfected with GFP-TDP25 for 24h, treated with SC75741 (5 μM) for 12h and 24h. Cell lysates were immunoblotted with indicated antibodies. The numbers under the blot represent the gray scale quantification (GFP/Tubulin).
- D. HEK293 WT cells were treated with 5 μ M SC75741 with or without, Bafilomycin A1 (100 nM), E-64D (10 μ M) for 5h. Cell lysates were immunoblotted with indicated antibodies. The numbers under the blot represent the gray scale quantification (LC3 II/LC3 I).

Figure S4 Α В HEK293 P62-/-(<u>eq</u>2.0-3XFlag-TDP-25 -2.0 (Keima red/Keima green) -1.5 -1.0 -0.5 -0.0 (Keima green/Keima 0.0 0.0 ns Fold Change ns Fold Change SC75741 Da HA 5 IP:Flag Flag 5 SC ISTA SCIPIAN DNSO DM50 DM50 SCIPIAN DM50 - SCISTAN HA 5 Input Flag 25 12h 12h 6h С D *** Average number of colocalization Average number of colocalization 15 15 (p62/TDP25/Lamp1) (p62/TDP25/LC3C) dots per cell 10 10 dots per cell 5 5 0 0 DMSÓ SC75741 5C75741

Figure S4. SC75741-induced TDP25 degradation depends on p62 and LC3C

A. HEK293 P62-/- cells were transfected with Keima-TDP25, pretreated with 1 μg/mL DOX for 24 h, treated with DMSO or 5 μM SC75741 for 6h and 12h, and the Keima-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. (data represent mean \pm SD; n = 7, ns, not significant, two-tailed t test).

- B. HEK293 WT cells were transfected with Flag-TDP25 and HA-tagged ATG8 family proteins for 24h, treated with or without SC75741 (5 μ M) for another 6h, the interaction between ATG8 family proteins and TDP25 were analyzed by immunoprecipitation.
- C. Quantification of the average number of colocalization among TDP25, p62, lamp1 in cells were analyzed by two-tailed t test. (data represent mean ± SD; DMSO (n = 10 cells), SC75741 (n = 10 cells), ***p < 0.001, two-tailed t test).
- D. Quantification of the average number of colocalization among TDP25, p62, LC3C in cells were analyzed by two-tailed t test. (data represent mean \pm SD; DMSO (n = 10 cells), SC75741 (n = 10 cells), **p < 0.01, two-tailed t test).